Cellectar Initiates Phase 1b Trial for Triple Negative Breast Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy CLRB?
Source: Newsfilter
- Trial Commencement: Cellectar Biosciences has announced the enrollment of the first patient in the Phase 1b trial of CLR 121125 aimed at treating triple negative breast cancer (TNBC), marking a significant milestone in the company's efforts in targeted cancer therapies.
- Mechanism Validation: CLR 125 is a proprietary Auger-emitting radioconjugate utilizing iodine-125 for intracellular delivery, capable of directly damaging tumor cell DNA; preclinical studies have shown significant tumor selectivity and activity in TNBC models without observed end-organ or hematologic toxicity.
- Dose Escalation Design: The trial features an open-label, dose-escalation design evaluating three different doses (32.75 mCi, 62.5 mCi, and 95 mCi), with approximately 15 patients per treatment arm, aiming to predict safety and efficacy through imaging assessments of tumor uptake and biodistribution.
- Urgent Market Need: With approximately 12% of breast cancer cases being TNBC and a 25% relapse rate post-standard treatments, the development of CLR 125 addresses a critical market need, presenting significant commercial opportunities for Cellectar.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLRB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLRB
About CLRB
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cellectar Initiates Phase 1b Trial for Triple Negative Breast Cancer
- Trial Commencement: Cellectar Biosciences has announced the enrollment of the first patient in the Phase 1b trial of CLR 121125 aimed at treating triple negative breast cancer (TNBC), marking a significant milestone in the company's efforts in targeted cancer therapies.
- Mechanism Validation: CLR 125 is a proprietary Auger-emitting radioconjugate utilizing iodine-125 for intracellular delivery, capable of directly damaging tumor cell DNA; preclinical studies have shown significant tumor selectivity and activity in TNBC models without observed end-organ or hematologic toxicity.
- Dose Escalation Design: The trial features an open-label, dose-escalation design evaluating three different doses (32.75 mCi, 62.5 mCi, and 95 mCi), with approximately 15 patients per treatment arm, aiming to predict safety and efficacy through imaging assessments of tumor uptake and biodistribution.
- Urgent Market Need: With approximately 12% of breast cancer cases being TNBC and a 25% relapse rate post-standard treatments, the development of CLR 125 addresses a critical market need, presenting significant commercial opportunities for Cellectar.
See More
Cellectar Biosciences Reports FY GAAP EPS of -$8.35
- Financial Performance: Cellectar Biosciences reported a FY GAAP EPS of -$8.35, indicating significant challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Flow Status: As of December 31, 2025, the company had cash and cash equivalents of $13.2 million, down from $23.3 million as of December 31, 2024, reflecting a decline in liquidity that may limit future investments and operational capabilities.
- Operational Funding Assurance: The company believes its cash balance as of December 31, 2025, is sufficient to fund its basic budgeted operations into the third quarter of 2026, indicating some short-term financial stability, though long-term sustainability remains a concern.
- Market Expectations: The financial data from Cellectar Biosciences may influence market expectations regarding its future development, particularly in investment decisions related to R&D and market promotion, prompting investors to closely monitor subsequent financial performance.
See More
Cellectar Biosciences Reports 2025 Financial Results and Progress
- Market Authorization Progress: Cellectar plans to submit a Conditional Marketing Authorization for iopofosine I 131 to the European Medicines Agency in Q3 2026, with potential EU commercialization in 2027, marking a significant advancement in the treatment of Waldenström Macroglobulinemia.
- Clinical Study Initiation: The company has initiated a Phase 1b dose-finding study for CLR 125 in Triple Negative Breast Cancer, with early data expected by mid-2026, demonstrating Cellectar's ongoing innovation in cancer treatment.
- Improved Financial Position: As of December 31, 2025, Cellectar reported cash and cash equivalents of $13.2 million, down from $23.3 million in 2024, but sufficient to fund basic operations into Q3 2026, indicating prudent financial management.
- Reduced R&D Expenses: Research and development expenses for 2025 were approximately $11.5 million, significantly lower than $26.1 million in 2024, primarily due to reduced activity in the CLOVER WaM clinical study, reflecting a strategic adjustment in resource allocation.
See More
Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane
- Acquisition Proposal: Great Dane's submission of a non-binding acquisition letter to Bark Inc has led to a 19.9% surge in Bark's pre-market share price to $0.74, indicating strong market enthusiasm for the potential acquisition.
- Market Reaction: The significant rise in Bark Inc's stock price reflects investor optimism regarding the company's future, which may also attract more investor attention and enhance market liquidity for the stock.
- Industry Dynamics: In pre-market trading, Signing Day Sports Inc saw a 43.7% increase, while Ping An Biomedical Co Ltd rose 34.3%, highlighting strong market interest in the biotech and sports sectors, which could influence Bark Inc's market positioning.
- Investor Confidence: The rebound in Bark Inc's stock price may bolster investor confidence in the company, especially after recent market volatility, as the acquisition proposal provides new momentum for future growth.
See More
Cellectar Plans to Submit iopofosine I 131 for European Approval in 3Q 2026
- Regulatory Milestone: Cellectar plans to submit a Conditional Marketing Authorization application for iopofosine I 131 to the EMA in 3Q 2026, with potential approval in early 2027, positioning the company to capture significant market share among WM patients in Europe.
- Clinical Advancement: The company anticipates dosing the first patients in a Phase 1b study of CLR 125 for triple-negative breast cancer in 1Q 2026, with interim data expected in mid-2026, further validating its therapeutic potential in a challenging market.
- Funding Support: Cellectar raised approximately $15.2 million through financings and warrant exercises to support pipeline development and regulatory milestones, ensuring its continued growth in the competitive biopharmaceutical landscape.
- Strategic Showcase: Cellectar will highlight its 2026 strategic initiatives at the upcoming Biotech Showcase, emphasizing its innovations in cancer treatment and market expansion potential, thereby boosting investor confidence.
See More
Cellectar Plans to Submit iopofosine I 131 for Conditional Approval in Europe by 3Q 2026
- Regulatory Milestone: Cellectar plans to submit a Conditional Marketing Authorization application for iopofosine I 131 to the EMA in 3Q 2026, with potential approval in early 2027, which would allow the company to access approximately 30 countries, significantly expanding its market share in WM treatment.
- Clinical Progress: The company anticipates dosing the first patients in the Phase 1b study of CLR 125 for triple-negative breast cancer in 1Q 2026, with interim data expected in mid-2026, which will provide crucial support for the expansion of its product line in this high-demand area.
- Funding Support: Cellectar raised approximately $15.2 million through financings and warrant exercises to support pipeline development and regulatory milestones, ensuring adequate funding for future clinical trials and market launches.
- Strategic Showcase: Cellectar will highlight its strategic initiatives at the 2026 Biotech Showcase, with CEO James Caruso presenting a corporate update on January 14, 2025, showcasing the company's innovative advancements in WM and triple-negative breast cancer, further boosting investor confidence.
See More
Cellectar Initiates Phase 1b Trial for Triple Negative Breast Cancer
- Trial Commencement: Cellectar Biosciences has announced the enrollment of the first patient in the Phase 1b trial of CLR 121125 aimed at treating triple negative breast cancer (TNBC), marking a significant milestone in the company's efforts in targeted cancer therapies.
- Mechanism Validation: CLR 125 is a proprietary Auger-emitting radioconjugate utilizing iodine-125 for intracellular delivery, capable of directly damaging tumor cell DNA; preclinical studies have shown significant tumor selectivity and activity in TNBC models without observed end-organ or hematologic toxicity.
- Dose Escalation Design: The trial features an open-label, dose-escalation design evaluating three different doses (32.75 mCi, 62.5 mCi, and 95 mCi), with approximately 15 patients per treatment arm, aiming to predict safety and efficacy through imaging assessments of tumor uptake and biodistribution.
- Urgent Market Need: With approximately 12% of breast cancer cases being TNBC and a 25% relapse rate post-standard treatments, the development of CLR 125 addresses a critical market need, presenting significant commercial opportunities for Cellectar.
See More
Cellectar Biosciences Reports FY GAAP EPS of -$8.35
- Financial Performance: Cellectar Biosciences reported a FY GAAP EPS of -$8.35, indicating significant challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Flow Status: As of December 31, 2025, the company had cash and cash equivalents of $13.2 million, down from $23.3 million as of December 31, 2024, reflecting a decline in liquidity that may limit future investments and operational capabilities.
- Operational Funding Assurance: The company believes its cash balance as of December 31, 2025, is sufficient to fund its basic budgeted operations into the third quarter of 2026, indicating some short-term financial stability, though long-term sustainability remains a concern.
- Market Expectations: The financial data from Cellectar Biosciences may influence market expectations regarding its future development, particularly in investment decisions related to R&D and market promotion, prompting investors to closely monitor subsequent financial performance.
See More
Cellectar Biosciences Reports 2025 Financial Results and Progress
- Market Authorization Progress: Cellectar plans to submit a Conditional Marketing Authorization for iopofosine I 131 to the European Medicines Agency in Q3 2026, with potential EU commercialization in 2027, marking a significant advancement in the treatment of Waldenström Macroglobulinemia.
- Clinical Study Initiation: The company has initiated a Phase 1b dose-finding study for CLR 125 in Triple Negative Breast Cancer, with early data expected by mid-2026, demonstrating Cellectar's ongoing innovation in cancer treatment.
- Improved Financial Position: As of December 31, 2025, Cellectar reported cash and cash equivalents of $13.2 million, down from $23.3 million in 2024, but sufficient to fund basic operations into Q3 2026, indicating prudent financial management.
- Reduced R&D Expenses: Research and development expenses for 2025 were approximately $11.5 million, significantly lower than $26.1 million in 2024, primarily due to reduced activity in the CLOVER WaM clinical study, reflecting a strategic adjustment in resource allocation.
See More
Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane
- Acquisition Proposal: Great Dane's submission of a non-binding acquisition letter to Bark Inc has led to a 19.9% surge in Bark's pre-market share price to $0.74, indicating strong market enthusiasm for the potential acquisition.
- Market Reaction: The significant rise in Bark Inc's stock price reflects investor optimism regarding the company's future, which may also attract more investor attention and enhance market liquidity for the stock.
- Industry Dynamics: In pre-market trading, Signing Day Sports Inc saw a 43.7% increase, while Ping An Biomedical Co Ltd rose 34.3%, highlighting strong market interest in the biotech and sports sectors, which could influence Bark Inc's market positioning.
- Investor Confidence: The rebound in Bark Inc's stock price may bolster investor confidence in the company, especially after recent market volatility, as the acquisition proposal provides new momentum for future growth.
See More
Cellectar Plans to Submit iopofosine I 131 for European Approval in 3Q 2026
- Regulatory Milestone: Cellectar plans to submit a Conditional Marketing Authorization application for iopofosine I 131 to the EMA in 3Q 2026, with potential approval in early 2027, positioning the company to capture significant market share among WM patients in Europe.
- Clinical Advancement: The company anticipates dosing the first patients in a Phase 1b study of CLR 125 for triple-negative breast cancer in 1Q 2026, with interim data expected in mid-2026, further validating its therapeutic potential in a challenging market.
- Funding Support: Cellectar raised approximately $15.2 million through financings and warrant exercises to support pipeline development and regulatory milestones, ensuring its continued growth in the competitive biopharmaceutical landscape.
- Strategic Showcase: Cellectar will highlight its 2026 strategic initiatives at the upcoming Biotech Showcase, emphasizing its innovations in cancer treatment and market expansion potential, thereby boosting investor confidence.
See More
Cellectar Plans to Submit iopofosine I 131 for Conditional Approval in Europe by 3Q 2026
- Regulatory Milestone: Cellectar plans to submit a Conditional Marketing Authorization application for iopofosine I 131 to the EMA in 3Q 2026, with potential approval in early 2027, which would allow the company to access approximately 30 countries, significantly expanding its market share in WM treatment.
- Clinical Progress: The company anticipates dosing the first patients in the Phase 1b study of CLR 125 for triple-negative breast cancer in 1Q 2026, with interim data expected in mid-2026, which will provide crucial support for the expansion of its product line in this high-demand area.
- Funding Support: Cellectar raised approximately $15.2 million through financings and warrant exercises to support pipeline development and regulatory milestones, ensuring adequate funding for future clinical trials and market launches.
- Strategic Showcase: Cellectar will highlight its strategic initiatives at the 2026 Biotech Showcase, with CEO James Caruso presenting a corporate update on January 14, 2025, showcasing the company's innovative advancements in WM and triple-negative breast cancer, further boosting investor confidence.
See More
